NCT03617315

Brief Summary

A total of 50 eyes were analyzed (25 patients). The subjects selected were over 18 years of age. No gender distinction was made in the choice of subjects. All subjects were carriers of silicone hydrogel contact lenses. The antecedents of the eye diseases not identified, neither the previous eye surgeries nor the systemic or ocular medication. All patients read, understood and signed an informed consent form of the study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2017

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 20, 2018

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 16, 2018

Completed
21 days until next milestone

First Posted

Study publicly available on registry

August 6, 2018

Completed
Last Updated

August 14, 2018

Status Verified

August 1, 2018

Enrollment Period

4 months

First QC Date

July 16, 2018

Last Update Submit

August 10, 2018

Conditions

Keywords

Crosslinked Hyaluronic AcidMeibomian Gland DisfunctionLubricantsContact LensDry Eye

Outcome Measures

Primary Outcomes (3)

  • Schirmer Test

    Measurement of the tear volume. Scale between 0 and 30 milimeters (mm) Higger is better

    6 weeks

  • Break Up Time Test

    Lacrimal rupture time of the lipid layer. Scale between 0 and 25 seconds (s) Higger is better

    6 weeks

  • Ocular Surface Disease Index

    Dry Eye Score from Questionnaire. Scale between 0 and 50 points. Higger is worse

    6 weeks

Study Arms (2)

Hyaluronic Acid

EXPERIMENTAL

One drop application of Hyaluronic acid + Galact-Xyloglucan with a dosage of 3 times a day for 45 days

Drug: Hylauronic Acid

CrossLinked Hyalurnic Acid

EXPERIMENTAL

One drop application of Crosslinked Hylauronic Acid + Liposomes with a dosage of 3 times a day for 45 days

Drug: Hylauronic Acid

Interventions

Schirmer Test, BUT test and OSDI test. Previous and After treatment

Also known as: Galacto-Xiloglucan, HA+GX
CrossLinked Hyalurnic AcidHyaluronic Acid

Eligibility Criteria

Age18 Years - 30 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Ocular Surface Disease Index over 15
  • Dysfunction of the meibomian gland
  • User contact lenses silicone hydrogel
  • User of digital screens for a long timeç

You may not qualify if:

  • Previous eye surgeries
  • Previous eye pathologies
  • User of artificial tears
  • User of ophthalmic gels

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

José-María Sánchez-González

Seville, Seville, 41012, Spain

Location

Related Publications (8)

  • Fallacara A, Vertuani S, Panozzo G, Pecorelli A, Valacchi G, Manfredini S. Novel Artificial Tears Containing Cross-Linked Hyaluronic Acid: An In Vitro Re-Epithelialization Study. Molecules. 2017 Nov 30;22(12):2104. doi: 10.3390/molecules22122104.

  • Uccello-Barretta G, Balzano F, Vanni L, Sanso M. Mucoadhesive properties of tamarind-seed polysaccharide/hyaluronic acid mixtures: A nuclear magnetic resonance spectroscopy investigation. Carbohydr Polym. 2013 Jan 16;91(2):568-72. doi: 10.1016/j.carbpol.2012.07.085. Epub 2012 Aug 25.

  • Doan S, Bremond-Gignac D, Chiambaretta F. Comparison of the effect of a hyaluronate-trehalose solution to hyaluronate alone on Ocular Surface Disease Index in patients with moderate to severe dry eye disease. Curr Med Res Opin. 2018 Aug;34(8):1373-1376. doi: 10.1080/03007995.2018.1434496. Epub 2018 Feb 7.

  • Jacobi C, Kruse FE, Cursiefen C. Prospective, randomized, controlled comparison of SYSTANE UD eye drops versus VISINE INTENSIV 1% EDO eye drops for the treatment of moderate dry eye. J Ocul Pharmacol Ther. 2012 Dec;28(6):598-603. doi: 10.1089/jop.2012.0066. Epub 2012 Jul 19.

  • Postorino EI, Rania L, Aragona E, Mannucci C, Alibrandi A, Calapai G, Puzzolo D, Aragona P. Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol. 2018 Jan;28(1):25-31. doi: 10.5301/ejo.5001011. Epub 2018 Feb 19.

  • Acar D, Molina-Martinez IT, Gomez-Ballesteros M, Guzman-Navarro M, Benitez-Del-Castillo JM, Herrero-Vanrell R. Novel liposome-based and in situ gelling artificial tear formulation for dry eye disease treatment. Cont Lens Anterior Eye. 2018 Feb;41(1):93-96. doi: 10.1016/j.clae.2017.11.004. Epub 2017 Dec 6.

  • Rolando M, Valente C. Establishing the tolerability and performance of tamarind seed polysaccharide (TSP) in treating dry eye syndrome: results of a clinical study. BMC Ophthalmol. 2007 Mar 29;7:5. doi: 10.1186/1471-2415-7-5.

  • Williams DL, Mann BK. Efficacy of a crosslinked hyaluronic acid-based hydrogel as a tear film supplement: a masked controlled study. PLoS One. 2014 Jun 10;9(6):e99766. doi: 10.1371/journal.pone.0099766. eCollection 2014.

MeSH Terms

Conditions

Dry Eye SyndromesMeibomian Gland Dysfunction

Interventions

poly(vinyl alcohol)-hylauronic acid

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye DiseasesEyelid Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
The patients did not know the artificial tear that should be applied. The researcher in charge of processing the results and drawing the conclusions did not know the name of the artificial tears
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Contralateral Eye Study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD Optometry and Vision Science

Study Record Dates

First Submitted

July 16, 2018

First Posted

August 6, 2018

Study Start

October 1, 2017

Primary Completion

February 1, 2018

Study Completion

March 20, 2018

Last Updated

August 14, 2018

Record last verified: 2018-08

Data Sharing

IPD Sharing
Will not share

Share with University of Seville Researches through the virtual learning platform

Locations